Acción TVTX TRAVERE THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 21:41:48 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
8,23 USD +3,39 % Gráfico intradía de Travere Therapeutics, Inc. +18,13 % -8,68 %
05/06 Transcript : Travere Therapeutics, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
15/05 Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics : Corporate Overview – May 2024
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics : Equity Incentive Plan - Form 8-K
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Travere: Q1 Earnings Snapshot
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M
Travere Therapeutics Reports First Quarter 2024 Financial Results
Travere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción TVTX
  4. Noticias Travere Therapeutics, Inc.
  5. Otros idiomas